Neurosciences revenue trends
In 4Q17, Novartis’s Neuroscience segment generated revenues of $850 million compared to $841 million in 4Q16, which reflected ~1% growth on a YoY basis. In fiscal 2017, Novartis’s neuroscience portfolio reported revenues of $3.3 billion compared to $3.2 billion in 2016, which reflected ~2% growth on a YoY basis. In 4Q17, Gilenya reported revenues of $825 million compared to $810 million in 4Q16, which reflected ~2% growth on a YoY basis and ~3% growth quarter-over-quarter. In fiscal 2017, Gilenya reported revenues of $3.2 billion compared to $3.1 billion in 2016, which is ~2% growth on a YoY basis.
Gilenya is used for the treatment of individuals with relapsing forms of multiple sclerosis. Presently, Gilenya is approved in 80 countries worldwide. According to Novartis’s estimates, over 225,000 individuals have been treated with Gilenya. Novartis also estimates that Gilenya’s total patient exposure stands at over 508,000 patients. In the multiple sclerosis markets, Gilenya’s peers include Sanofi’s (SNY) Aubagio, Biogen’s (BIIB) Tysabri and Tecfidera, and Teva Pharmaceuticals’ (TEVA) Copaxone.
Cardio-metabolic segment revenue trends
In 4Q17, Novartis’s (NVS) Cardio-Metabolic segment generated revenues of $190 million compared to $74 million in 4Q16. In fiscal 2017, the Cardio-Metabolic segment reported revenues of $524 million compared to $185 million in 2016.
In 4Q17, Novartis’s Entresto generated revenues of $185 million compared to $68 million in 4Q16. In 2017, Entresto reported revenues of $507 million compared to $170 million in 2016. The increasing adoption of Entresto by physicians in the US and Europe markets primarily led to the revenue growth of the drug.
According to Novartis, over 420,000 individuals with heart failure and reduced ejection take Entresto. Currently, Entresto is approved in more than 100 countries worldwide.
In 4Q17, Novartis launched Entresto in China and Ireland. According to Novartis’s estimates, China has over one million eligible patients who can use Entresto. The new launches are expected to further boost the sales growth of Entresto.